All In Biotech

Drug Trial Radar · NCT01970111

An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Last checked: Nov 19, 2026Latest source record: Apr 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

Not stated

Start

Not stated

Primary completion

Jul 2015

Sponsor

Sponsor type
Industry
First posted
Oct 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Who can join
All sexes, from 20 years

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.

Conditions

  • Spinocerebellar Degeneration

Interventions

  • KPS-0373, High doseDrug

  • KPS-0373, Low doseDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SARA (Scale for the Assessment and Rating of Ataxia)Time frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Tokyo and Other Japanese Cities, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.